IN2015DN00337A - - Google Patents
Info
- Publication number
- IN2015DN00337A IN2015DN00337A IN337DEN2015A IN2015DN00337A IN 2015DN00337 A IN2015DN00337 A IN 2015DN00337A IN 337DEN2015 A IN337DEN2015 A IN 337DEN2015A IN 2015DN00337 A IN2015DN00337 A IN 2015DN00337A
- Authority
- IN
- India
- Prior art keywords
- disorders
- formula
- tautomers
- prodrugs
- oxides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
The present invention relates to compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharma ceutically acceptable salts thereof, where in formula I the variables R 1, R2, R3, R4 and R5 are as defined in the claims and where X is C-R6 or N,Y is C-R7 or N, where R6 and R7 are, inter alia, hydrogen, halogen, alkoxy, haloalkoxy and the like. The compounds of the formula I, the N-oxides, tautomers,the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase o type 1OA and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical dis - orders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261684290P | 2012-08-17 | 2012-08-17 | |
| PCT/EP2013/067122 WO2014027078A1 (en) | 2012-08-17 | 2013-08-16 | Inhibitor compounds of phosphodiesterase type 10a |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN00337A true IN2015DN00337A (en) | 2015-06-12 |
Family
ID=48986145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN337DEN2015 IN2015DN00337A (en) | 2012-08-17 | 2013-08-16 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US9464085B2 (en) |
| EP (1) | EP2885299B1 (en) |
| JP (1) | JP2015524833A (en) |
| KR (1) | KR20150042798A (en) |
| CN (1) | CN104684912A (en) |
| AR (1) | AR092167A1 (en) |
| AU (1) | AU2013304043A1 (en) |
| BR (1) | BR112015003236A2 (en) |
| CA (1) | CA2879485A1 (en) |
| CL (1) | CL2015000370A1 (en) |
| CR (1) | CR20150082A (en) |
| DO (1) | DOP2015000029A (en) |
| EC (1) | ECSP15010205A (en) |
| HK (1) | HK1211284A1 (en) |
| IL (1) | IL236946A0 (en) |
| IN (1) | IN2015DN00337A (en) |
| MX (1) | MX2015002000A (en) |
| PE (1) | PE20151069A1 (en) |
| PH (1) | PH12015500348A1 (en) |
| RU (1) | RU2015109135A (en) |
| SG (1) | SG11201501111YA (en) |
| TW (1) | TW201412742A (en) |
| UY (1) | UY34980A (en) |
| WO (1) | WO2014027078A1 (en) |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030032579A1 (en) | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| US20030166476A1 (en) | 2002-01-31 | 2003-09-04 | Winemiller Mark D. | Lubricating oil compositions with improved friction properties |
| US20070032404A1 (en) | 2003-07-31 | 2007-02-08 | Bayer Pharmaceuticals Corporation | Methods for treating diabetes and related disorders using pde10a inhibitors |
| US20090075980A1 (en) | 2003-10-03 | 2009-03-19 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and Analogs Thereof |
| WO2005120514A1 (en) | 2004-06-07 | 2005-12-22 | Pfizer Products Inc. | Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions |
| EP1802585A1 (en) | 2004-09-03 | 2007-07-04 | Memory Pharmaceuticals Corporation | 4-substituted 4,6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms |
| WO2007022280A1 (en) | 2005-08-16 | 2007-02-22 | Memory Pharmaceuticals Corporation | Phosphodiesterase 10 inhibitors |
| NL2000397C2 (en) | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclic heteroaryl compounds as PDE10 inhibitors. |
| WO2007082546A1 (en) | 2006-01-20 | 2007-07-26 | H. Lundbeck A/S | Use of tofisopam as a pde10a inhibitor |
| WO2007085954A2 (en) | 2006-01-27 | 2007-08-02 | Pfizer Products Inc. | Aminophthalazine derivative compounds |
| CA2643963A1 (en) | 2006-02-21 | 2007-08-30 | Amgen Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
| EP1991540A1 (en) | 2006-02-21 | 2008-11-19 | Amgen Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
| CA2641670A1 (en) | 2006-02-23 | 2007-08-30 | Pfizer Products Inc. | Substituted quinazolines as pde10 inhibitors |
| AU2007221049A1 (en) | 2006-02-28 | 2007-09-07 | Amgen Inc. | Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors |
| US20070265258A1 (en) | 2006-03-06 | 2007-11-15 | Ruiping Liu | Quinazoline derivatives as phosphodiesterase 10 inhibitors |
| AU2007223801A1 (en) | 2006-03-08 | 2007-09-13 | Amgen Inc. | Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors |
| TW200817400A (en) | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| TW200815436A (en) * | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| JP2009541481A (en) | 2006-06-26 | 2009-11-26 | ファイザー・プロダクツ・インク | Tricyclic heteroaryl compounds as PDE10 inhibitors |
| US20080090834A1 (en) | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| ES2392553T3 (en) | 2006-07-10 | 2012-12-11 | H. Lundbeck A/S | Derivatives (3-aryl-piperazine-1-yl) of 6,7-dialkoxyquinazoline, 6,7-dialkoxyphthalazine and 6,7-dialkoxyisoquinoline |
| WO2008020302A2 (en) | 2006-08-17 | 2008-02-21 | Pfizer Products Inc. | Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors |
| WO2009025823A1 (en) | 2007-08-21 | 2009-02-26 | Amgen Inc. | Phosphodiesterase 10 inhibitors |
| WO2009025839A2 (en) | 2007-08-22 | 2009-02-26 | Amgen Inc. | Phosphodiesterase 10 inhibitors |
| WO2009029214A1 (en) | 2007-08-23 | 2009-03-05 | Amgen Inc. | Isoquinolone derivatives as phosphodiesterase 10 inhibitors |
| TW200918519A (en) | 2007-09-19 | 2009-05-01 | Lundbeck & Co As H | Cyanoisoquinoline |
| US20090143361A1 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 |
| WO2009068320A1 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10 |
| EP2225248A1 (en) | 2007-11-30 | 2010-09-08 | Wyeth LLC | Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10 |
| US20090143392A1 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Methods of Treating Obesity and Metabolic Disorders |
| US20100120763A1 (en) | 2008-11-07 | 2010-05-13 | Wyeth | Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases |
| WO2011008597A1 (en) | 2009-07-14 | 2011-01-20 | Schering Corporation | Dihydroimidazoisoquinoline derivatives useful as pde10 inhibitors |
| TW201204727A (en) | 2010-03-10 | 2012-02-01 | Kalypsys Inc | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| DE102010025786A1 (en) | 2010-07-01 | 2012-01-05 | Merck Patent Gmbh | Pyrazolochinoline |
-
2013
- 2013-08-15 UY UY0001034980A patent/UY34980A/en not_active Application Discontinuation
- 2013-08-15 US US13/968,242 patent/US9464085B2/en active Active
- 2013-08-16 WO PCT/EP2013/067122 patent/WO2014027078A1/en active Application Filing
- 2013-08-16 AR ARP130102932A patent/AR092167A1/en unknown
- 2013-08-16 RU RU2015109135A patent/RU2015109135A/en not_active Application Discontinuation
- 2013-08-16 IN IN337DEN2015 patent/IN2015DN00337A/en unknown
- 2013-08-16 JP JP2015526996A patent/JP2015524833A/en not_active Withdrawn
- 2013-08-16 PE PE2015000204A patent/PE20151069A1/en not_active Application Discontinuation
- 2013-08-16 SG SG11201501111YA patent/SG11201501111YA/en unknown
- 2013-08-16 EP EP13750071.6A patent/EP2885299B1/en not_active Not-in-force
- 2013-08-16 CN CN201380043926.2A patent/CN104684912A/en active Pending
- 2013-08-16 KR KR20157004416A patent/KR20150042798A/en not_active Application Discontinuation
- 2013-08-16 AU AU2013304043A patent/AU2013304043A1/en not_active Abandoned
- 2013-08-16 CA CA2879485A patent/CA2879485A1/en not_active Abandoned
- 2013-08-16 BR BR112015003236A patent/BR112015003236A2/en not_active IP Right Cessation
- 2013-08-16 MX MX2015002000A patent/MX2015002000A/en unknown
- 2013-08-16 TW TW102129554A patent/TW201412742A/en unknown
-
2015
- 2015-01-27 IL IL236946A patent/IL236946A0/en unknown
- 2015-02-16 DO DO2015000029A patent/DOP2015000029A/en unknown
- 2015-02-16 CL CL2015000370A patent/CL2015000370A1/en unknown
- 2015-02-17 PH PH12015500348A patent/PH12015500348A1/en unknown
- 2015-02-19 CR CR20150082A patent/CR20150082A/en unknown
- 2015-03-17 EC ECIEPI201510205A patent/ECSP15010205A/en unknown
- 2015-12-04 HK HK15111990.0A patent/HK1211284A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013304043A1 (en) | 2015-02-05 |
| US9464085B2 (en) | 2016-10-11 |
| MX2015002000A (en) | 2015-10-09 |
| CL2015000370A1 (en) | 2015-10-02 |
| KR20150042798A (en) | 2015-04-21 |
| PH12015500348A1 (en) | 2015-04-20 |
| PE20151069A1 (en) | 2015-08-29 |
| CA2879485A1 (en) | 2014-02-20 |
| IL236946A0 (en) | 2015-03-31 |
| CN104684912A (en) | 2015-06-03 |
| TW201412742A (en) | 2014-04-01 |
| DOP2015000029A (en) | 2015-03-15 |
| ECSP15010205A (en) | 2016-01-29 |
| BR112015003236A2 (en) | 2017-07-04 |
| EP2885299A1 (en) | 2015-06-24 |
| JP2015524833A (en) | 2015-08-27 |
| UY34980A (en) | 2014-03-31 |
| RU2015109135A (en) | 2016-10-10 |
| EP2885299B1 (en) | 2017-04-05 |
| CR20150082A (en) | 2015-05-25 |
| WO2014027078A1 (en) | 2014-02-20 |
| AR092167A1 (en) | 2015-03-25 |
| HK1211284A1 (en) | 2016-05-20 |
| US20140051695A1 (en) | 2014-02-20 |
| SG11201501111YA (en) | 2015-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015012008A (en) | Novel inhibitor compounds of phosphodiesterase type 10a. | |
| PH12015501962A1 (en) | Novel inhibitor compounds of phosphodiesterase type 10a | |
| MX2010009207A (en) | Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors. | |
| AU2012277802A8 (en) | Novel inhibitor compounds of phosphodiesterase type 10A | |
| PH12015502502A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
| MX2012012952A (en) | 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds. | |
| MX2012001070A (en) | Oxazine derivatives and their use as bace inhibitors for the treatment of neurological disorders. | |
| MX2013008056A (en) | 1,4-oxazepines as bace1 and/or bace2 inhibitors. | |
| HK1138262A1 (en) | Novel phosphodiesterase inhibitors | |
| TW200730506A (en) | Compounds and uses thereof | |
| MX355142B (en) | Substituted heterocyclic acetamides as kappa opioid receptor (kor) agonists. | |
| MX360912B (en) | Substituted pyridopyrimidine compounds and their use as flt3 inhibitors. | |
| MY167396A (en) | Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament | |
| PH12015500085A1 (en) | 5-ht3 receptor antagonists | |
| WO2008155572A3 (en) | Fused quinoline derivatives useful as gaba modulators | |
| HK1164721A1 (en) | Therapeutic uses of quinazolinedione derivatives | |
| MY193754A (en) | Treatment for parkinson's disease | |
| PH12019500004A1 (en) | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases | |
| MX341341B (en) | Benzamide derivatives and their use as hsp90 inhibtors. | |
| MX2015003419A (en) | Novel inhibitor compounds of phosphodiesterase type 10a. | |
| IN2014DN09826A (en) | ||
| IN2015DN00337A (en) | ||
| NZ624124A (en) | Heterocyclic carboxamides useful as inhibitors of phosphodiesterase type 10a | |
| TH127359B (en) | 1,2,4-triazolo [4,3-a] derivatives, and their use as a post-Cardiff allosteric modulator of MGLUR2 sensory units. | |
| TN2011000668A1 (en) | Oxazine derivatives and their use as bace inhibitors for the treatment of neurological disorders |